Fibromyalgia: Evolving concepts over the past 2 decades

CMAJ. Canadian Medical Association Journal

Volumn 185, Issue 13, 2013, Pages

  Fitzcharles, Mary Ann ^a,b   Ste Marie, Peter A ^c,d   Pereira, John X ^d  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^c UNIVERSITÉ DE MONTRÉAL   (Canada)

^d UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ANALGESIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; CANNABIS; CITALOPRAM; DULOXETINE; FLUOXETINE; GABAPENTIN; MILNACIPRAN; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PAROXETINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRAMADOL; TRICYCLIC ANTIDEPRESSANT AGENT;

ACUPUNCTURE; COGNITIVE DEFECT; DELAYED DIAGNOSIS; FATIGUE; FIBROMYALGIA; GENETIC PREDISPOSITION; HEALTH CARE COST; HUMAN; HYPOTHALAMUS HYPOPHYSIS SYSTEM; LABORATORY TEST; MOOD DISORDER; PATHOGENESIS; PHYSICAL EXAMINATION; PRIMARY MEDICAL CARE; QUALITY OF LIFE; REVIEW; SLEEP DISORDER; STRESS; TRANSCUTANEOUS NERVE STIMULATION; UNSPECIFIED SIDE EFFECT;

EID: 84884571742     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.121414     Document Type: Review

References (54)

1. Price DD, Staud R. Neurobiology of fibromyalgia syndrome. J Rheumatol Suppl 2005;75:22-8.
2. Sommer C, Häuser W, Burgmer M, et al. Etiology and pathophysiology of fibromyalgia syndrome [article in German]. Schmerz 2012;26:259-67.
3. Ceko M, Bushnell MC, Gracely RH. Neurobiology underlying fibromyalgia symptoms. Pain Res Treat 2011; Oct. 27 [Epub ahead of print].
4. Perrot S, Dickenson AH, Bennett RM. Fibromyalgia: harmonizing science with clinical practice considerations. Pain Pract 2008;8:177-89.
5. Wolfe F, Smythe HA, Yunus MB, et al. The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum 1990;33:160-72.
6. Wolfe F, Clauw DJ, Fitzcharles M-A, et al. The American College of Rheumatology Preliminary Diagnostic Criteria for Fibromyalgia and Measurement of Symptom Severity. Arthritis Care Res (Hoboken) 2010;62:600-10.
7. Mease P, Arnold LM, Choy EH, et al. Fibromyalgia syndrome module at OMERACT 9: domain construct. J Rheumatol 2009;36:2318-29.
8. McNally JD, Matheson DA, Bakowsky VS. The epidemiology of self-reported fibromyalgia in Canada. Chronic Dis Can 2006;27:9-16.
9. Lachaine J, Beauchemin C, Landry P-A. Clinical and economic characteristics of patients with fibromyalgia syndrome. Clin J Pain 2010;26:284-90.
10. Walitt B, Fitzcharles MA, Hassett AL, et al. The longitudinal outcome of fibromyalgia: a study of 1555 patients. J Rheumatol 2011;38:2238-46.
11. Fitzcharles M-A, Ste-Marie PA, Goldenberg DL, et al. Canadian Guidelines for the Diagnosis and Management of Fibromyalgia Syndrome: executive summary. Pain Res Manag. In press.
12. Oxford Centre for Evidence-Based Medicine Levels of Evidence Working Group. The Oxford 2011 Levels of Evidence. Oxford (UK): Oxford Centre for Evidence-Based Medicine. Available: www.cebm.net/index.aspx?o=5653 (accessed 2013 Jan. 20).
13. Wolfe F, Hauser W. Fibromyalgia diagnosis and diagnostic criteria. Ann Med 2011;43:495-502.
14. Goldenberg DL. Diagnosis and differential diagnosis of fbro - myalgia. Am J Med 2009;122(Suppl 12):S14-21.
15. Moldofsky H. The signifcance of the sleeping-waking brain for the understanding of widespread musculoskeletal pain and fatigue in fibromyalgia syndrome and allied syndromes. Joint Bone Spine 2008;75:397-402.
16. Park DC, Glass JM, Minear M, et al. Cognitive function in fibromyalgia patients. Arthritis Rheum 2001;44:2125-33.
17. Epstein SA, Kay G, Clauw D, et al. Psychiatric disorders in patients with fibromyalgia. A multicenter investigation. Psychosomatics 1999;40:57-63.
18. Pöyhiä R, Da Costa D, Fitzcharles MA. Previous pain experience in women with fibromyalgia and infammatory arthritis and nonpainful controls. J Rheumatol 2001;28:1888-91.
19. Harth M, Nielson WR. The fibromyalgia tender points: Use them or lose them? A brief review of the controversy. J Rheumatol 2007;34:914-22.
20. Khostanteen I, Tunks ER, Goldsmith CH, et al. Fibromyalgia: Can one distinguish it from simulation? An observer-blind controlled study. J Rheumatol 2000;27:2671-6.
21. Shir Y, Fitzcharles MA. Should rheumatologists retain ownership of fibromyalgia? J Rheumatol 2009;36:667-70.
22. Dickenson A. Pain and its control. Curr Med Res Opin 2011;27:2075-8.
23. Goldenberg DL, Burckhardt C, Crofford L. Management of fibromyalgia syndrome. JAMA 2004;292:2388-95.
24. Häuser W, Bernardy K, Arnold B, et al. Effcacy of multicomponent treatment in fibromyalgia syndrome: a meta-analysis of randomized controlled clinical trials. Arthritis Rheum 2009;61:216-24.
25. Boomershine CS, Crofford LJ. A symptom-based approach to pharmacologic management of fibromyalgia. Nat Rev Rheumatol 2009;5:191-9.
26. Dobkin PL, Liu A, Abrahamowicz M, et al. Predictors of disability and pain six months after the end of treatment for fibromyalgia. Clin J Pain 2010;26:23-9.
27. Martínez MP, Sanchez AI, Miro E, et al. The relationship between the fear-avoidance model of pain and personality traits in fibromyalgia patients. J Clin Psychol Med Settings 2011;18:380-91.
28. Nüesch E, Hauser W, Bernardy K, et al. Comparative effcacy of pharmacological and non-pharmacological interventions in fibromyalgia syndrome: network meta-analysis. Ann Rheum Dis 2013:72;955-62.
29. De Silva V, El-Metwally A, Ernst E, et al. Evidence for the effcacy of complementary and alternative medicines in the management of fibromyalgia: a systematic review. Rheumatology (Oxford) 2010;49:1063-8.
30. Goldenberg DL, Clauw DJ, Fitzcharles MA. New concepts in pain research and pain management of the rheumatic diseases. Semin Arthritis Rheum 2011;41:319-34.
31. Rossy LA, Buckelew S P, Dorr N, et al. A meta-analysis of fibromyalgia treatment interventions. Ann Behav Med 1999;21:180-91.
32. Ramel J, Bannuru R, Griffth M, et al. Exercise for fibromyalgia pain: a meta-analysis of randomized controlled trials. Curr Rheumatol Rep 2009;5:188-93.
33. Bernardy K, Fuber N, Kollner V, et al. Effcacy of cognitivebehavioral therapies in fibromyalgia syndrome - a systematic review and metaanalysis of randomized controlled trials. J Rheumatol 2010;37:1991-2005.
34. Fitzcharles MA, Ste-Marie PA, Gamsa A, et al. Opioid use, misuse, and abuse in patients labeled as fibromyalgia. Am J Med 2011;124:955-60.
35. Bennett RM, Jones J, Turk DC, et al. An internet survey of 2, 596 people with fibromyalgia. BMC Musculoskelet Disord 2007;8:27.
36. Uçeyler N, Häuser W, Sommer C. A systematic review on the effectiveness of treatment with antidepressants in fibromyalgia syndrome. Arthritis Rheum 2008;59:1279-98.
37. Häuser W, Bernardy K, Uceyler N, et al. Treatment of fbro - myalgia syndrome with antidepressants: a meta-analysis. JAMA 2009;301:198-209.
38. Häuser W, Bernardy K, Uceyler N, et al. Treatment of fbro - myalgia syndrome with gabapentin and pregabalin - a metaanalysis of randomized controlled trials. Pain 2009;145:69-81.
39. Siler AC, Gardner H, Yanit K, et al. Systematic review of the comparative effectiveness of antiepileptic drugs for fibromyalgia. J Pain 2011;12:407-15.
40. Moore RA, Straube S, Wiffen PJ, et al. Pregabalin for acute and chronic pain in adults. Cochrane Database Syst Rev 2009;(3): CD007076.
41. Bennett RM, Friend R, Jones KD, et al. The Revised Fibromyalgia Impact Questionnaire (FIQR): validation and psychometric properties. Arthritis Res Ther 2009;11:R120.
42. Burckhardt CS, Clark SR, Bennett RM. The Fibromyalgia Impact Questionnaire: development and validation. J Rheumatol 1991;18:728-33.
43. Bruce B, Fries JF. The Stanford Health Assessment Questionnaire: dimensions and practical applications. Health Qual Life Outcomes 2003;1:20.
44. Geisser ME, Clauw DJ, Strand V, et al. Contributions of change in clinical status parameters to Patient Global Impression of Change (PGIC) scores among persons with fibromyalgia treated with milnacipran. Pain 2010;149:373-8.
45. Hidding A, van Santen M, De Klerk E, et al. Comparison between self-report measures and clinical observations of functional disability in ankylosing spondylitis, rheumatoid arthritis and fibromyalgia. J Rheumatol 1994;21:818-23.
46. Wolfe F, Anderson J, Harkness D, et al. Work and disability status of persons with fibromyalgia. J Rheumatol 1997;24:1171-8.
47. Gervais RO, Russell AS, Green P, et al. Effort testing in patients with fibromyalgia and disability incentives. J Rheumatol 2001;28:1892-9.
48. Fitzcharles MA, Ste-Marie PA, Shir Y. A medicolegal analysis of worker appeals for fibromyalgia as a compensable condition following workplace soft-tissue injury. J Rheumatol 2013;40:323-8.
49. Reisine S, Fifield J, Walsh S, et al. Employment and health status changes among women with fibromyalgia: a fve-year study. Arthritis Rheum 2008;59:1735-41.
50. Rutledge DN, Jones K, Jones CJ. Predicting high physical function in people with fibromyalgia. J Nurs Scholarsh 2007;39:319-24.
51. Torres X, Collado A, Arias A, et al. Pain locus of control predicts return to work among Spanish fibromyalgia patients after completion of a multidisciplinary pain program. Gen Hosp Psychiatry 2009;31:137-45.
52. Kurtze N, Gundersen KT, Svebak S. The impact of perceived physical dysfunction, health-related habits, and affective symptoms on employment status among fibromyalgia support group members. J Musculoskeletal Pain 2001;9:39-53.
53. Henriksson C, Burckhardt C. Impact of fibromyalgia on everyday life: a study of women in the USA and Sweden. Disabil Rehabil 1996;18:241-8.
54. Henriksson CM, Liedberg GM, Gerdle B. Women with fbro - myalgia: work and rehabilitation. Disabil Rehabil 2005;27:685-94.